Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
orgotein
- Development stage
- Unknown
- Lead developer
- GT Biopharma
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Administration
- Intraarticular, Intramuscular, Subcutaneous, Intravesical, Intralesional
01
Overview
Orgotein is a bovine-derived copper-zinc superoxide dismutase (SOD), an enzyme that catalyzes the conversion of the superoxide radical into hydrogen peroxide and molecular oxygen. This antioxidant activity helps protect tissues from oxidative stress and inflammation. Orgotein has been used as an anti-inflammatory agent in both veterinary and human medicine. It is administered primarily by local injection for conditions such as degenerative joint disorders (osteoarthritis), soft tissue inflammation, chronic bladder inflammations (cystitis), radiation-induced injuries, Peyronie’s disease, and other inflammatory or rheumatic diseases. Its mechanism of action involves neutralizing reactive oxygen species at sites of inflammation to reduce tissue damage[2][3][4][5][6][7].
- Brand names
- OntoseinOrmeteinPalosein
- Other names
- superoxide dismutase (bovine)copper zinc SODCu/Zn-superoxide dismutaseArtrolasi
02
Targets
Misfolded SOD1
Beyond the preview
Go deeper on orgotein.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on orgotein.